Anne Nunes - Oct 1, 2023 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
SVP, Chief Operations Officer
Signature
/s/ Anne Nunes
Stock symbol
ANIK
Transactions as of
Oct 1, 2023
Transactions value $
-$13,637
Form type
4
Date filed
10/3/2023, 04:31 PM
Previous filing
Jun 26, 2023
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +2.49K +75.65% $0.00 5.78K Oct 1, 2023 Direct F1
transaction ANIK Common Stock Tax liability -$13.6K -732 -12.66% $18.63 5.05K Oct 1, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -2.49K -100% $0.00* 0 Oct 1, 2023 Common Stock 2.49K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on October 1, 2021.
F2 Reflects an aggregate of 732 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on October 1, 2023.
F3 Reflects the closing price of ANIK common stock on September 29, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F4 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022.